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Abstract
Natural killer (NK) cell malignancies, particularly aggressive NK cell leukaemias and lymphomas, have poor prognoses.
Although recent regimens with L-asparaginase substantially improved outcomes, novel therapeutic approaches are still
needed to enhance clinical response. Resveratrol, a naturally occurring polyphenol, has been extensively studied for its anti-
inflammatory, cardioprotective and anti-cancer activities. In this study, we investigated the potential anti-tumour activities
of resveratrol against the NK cell lines KHYG-1, NKL, NK-92 and NK-YS. Resveratrol induced robust G0/G1 cell cycle arrest,
significantly suppressed cell proliferation and induced apoptosis in a dose- and time-dependent manner for all four cell
lines. In addition, resveratrol suppressed constitutively active STAT3 in all the cell lines and inhibited JAK2 phosphorylation
but had no effect on other upstream mediators of STAT3 activation, such as PTEN, TYK2, and JAK1. Resveratrol also induced
downregulation of the anti-apoptotic proteins MCL1 and survivin, two downstream effectors of the STAT3 pathway. Finally,
resveratrol induced synergistic effect on the apoptotic and antiproliferative activities of L-asparaginase against KHYG-1, NKL
and NK-92 cells. These results suggest that resveratrol may have therapeutic potential against NK cell malignancies.
Furthermore, our finding that resveratrol is a bonafide JAK2 inhibitor extends its potential benefits to other diseases with
dysregulated JAK2 signaling.
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Introduction
Natural killer (NK) cell malignancies are rare in Western
countries but relatively common in Asia. These neoplasms,
particularly the aggressive NK cell leukaemia/lymphoma subtype,
have poor prognoses [1–8]. Even when intensive combination
chemotherapies are performed, disease relapse and therapy
resistance remain frequent issues. Several L-asparaginase regimens
were recently shown to have curative potential but are often
associated with serious side effects that can be life-threatening
[5,8–11]. Therefore, new therapeutic agents with less toxicity and
greater efficacy are of particular interest.
Resveratrol, a natural polyphenol found in red grapes, berries,
peanuts and other fruits, has been extensively studied for its
antioxidant, anti-aging and anti-inflammatory activities. In addi-
tion, in vivo and in vitro studies showed that resveratrol possesses
potent anti-tumour activity against several malignancies. These
effects are mediated by targeting molecules involved in the
regulation of cell proliferation and survival, such as phosphatase
and tensin homologue (PTEN)/Akt, nuclear factor (NF)-kB and
signal transducer and activator of transcription 3 (STAT3) [12–
16]. Constitutive STAT3 activation plays a critical role in the
growth and survival of several cancers, including NK neoplasms
[17–24]. We present the first report of resveratrol efficacy in
eliminating NK cell malignancies by inhibiting the Janus kinase 2
(JAK2)/STAT3 pathway, and its notable effectiveness against
KHYG-1 cells resistant to L-asparaginase therapy.
Materials and Methods
Cell Lines
The NK cell lines NK-92 [20], KHYG-1 [25] (a generous gift
from Dr. Y. Isobe at Juntendo University, Tokyo, Japan), NKL
[20] (obtained from Dr. M. J. Robertson at the Bone Marrow
Transplantation Program, Indiana University, Indianapolis, IN,
USA) and NK-YS [20,26] were cultured in Iscove’s Modified
Dulbecco’s Medium supplemented with 20% fetal bovine serum,
100 mg/ml streptomycin, 100 IU/ml penicillin and 100 IU/ml
interleukin-2 (Millipore, Temecula, California, USA) at 37uC and
5% CO2.
Reagents
Resveratrol, protease inhibitor cocktail, phosphatase inhibitor
cocktail, anti-a tubulin antibody and anti-p53 antibody were
purchased from Sigma (Marlborough, MA, USA). L-asparaginase
was obtained from ITSI-Biosciences (Johnstown, PA, USA).
AG490 was purchased from Merck Millipore (Temecula,
California, USA). Antibodies against survivin, myeloid leukaemia
cell differentiation protein 1 (MCL1), p21 Waf1/Cip1, p53, cdc2,
cdk2, Bcl-2, Bcl-10, cleaved caspase-3 (Asp175), phosphorylated
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STAT3 (Tyr705), acetylated STAT3 (Lys685), phosphorylated
PTEN (Ser380/Thr382/383), phosphorylated tyrosine kinase 2
(TYK2, Tyr1054/1055), phosphorylated Akt (Thr308), phosphor-
ylated JAK1 (Tyr1022/1023), total JAK1, and phosphorylated
JAK2 (Tyr1007/1008) were acquired from Cell Signaling
Technology (Danvers, MA, USA). Anti-total JAK2 antibody was
purchased from GenScript (Piscataway, NJ, USA). Anti-cdk3
antibody was obtained from Genetex (San Antonio, Texas). Anti-
STAT3 and anti-murine double minute (Mdm2) antibodies were
purchased from Protein Express (Kisarazu, Chiba, Japan) and
Acris Antibodies (San Diego, CA, USA), respectively.
Transient Transfection of STAT3 siRNA
NKL cells were transfected with STAT3 siRNA 100 nM (Cell
Signaling Technology) by electroporation using a Bio-Rad Pulser
II (Bio Rad, Hercules, CA) as previously described [27]. Non-
specific siRNA (Cell Signaling Technology) was used as a negative
control. Protein extraction was performed at 48 h of transfection.
Western blotting was used to examine the efficiency of trans-
fection.
Cell Proliferation Assay
Cells were cultured in the absence or presence of increasing
concentrations of resveratrol for 48 h. Cell viability was de-
termined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT, Roche, Basel, Switzerland) according to
the manufacturer’s instructions. Cells were also treated with
50 mM of resveratrol and their proliferation assessed at different
exposure times. The inhibitory rate was calculated as follows:
inhibitory rate (%) = [(A2B)/A] 6100, where A is the mean
optical density of control cells and B is the mean optical density of
test sample cells.
Annexin V Staining
Cells at a density of 56105/ml were treated with various
concentrations of resveratrol, L-asparaginase or AG490 at the
indicated times. The percentage of apoptosis was measured by
flow cytometry using annexin V-FITC (Invitrogen, Carlsbad, CA,
USA) and 7-aminoactinomycin D (BD Pharmingen Biosciences,
San Diego, CA, USA) according to the manufacturer’s instruc-
tions.
Synergistic effect between resveratrol and L-asparaginase was
determined by the cooperative index (CI) based on the Chou-
Talalay method [28,29]. CI = sum of apoptosis of single agent
treatment/apoptosis upon combined treatment. When CI,1,
CI= 1, and CI.1, the effects were defined as synergistic, additive,
and antagonistic respectively.
Giemsa Staining
Cells were treated with 50 mM of resveratrol for 12, 24 and
48 h, with untreated cells as a control. The cells were then
collected, resuspended in phosphate buffered solution and
centrifuged using cytospin at 800 rpm for 8 min to adhere on
microscopic slides. The cells were then air dried, fixed with
methanol, stained with Giemsa (Merck) for 20 min, rinsed in water
and air dried again. To evaluate apoptosis, morphological changes
were assessed under a light microscope.
Western Blotting Analysis
Cells were treated with 50 mM of resveratrol for the indicated
times. After treatment, whole cell protein samples were prepared
by lysing cells in M-PERH Mammalian Protein Extraction
Reagent (Pierce, Rockford, IL, USA) supplemented with phos-
phatase inhibitor cocktail and protease inhibitor cocktail (Sigma)
for 30 min at 4uC. 50 mg of total cellular protein was separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to polyvinylidene fluoride membranes
(Millipore). Milk-blocked blots were incubated at 4uC overnight
with primary antibodies and then with appropriate horseradish
peroxidase-conjugated secondary antibodies (anti-mouse IgG was
obtained from KPL, Gaithersburg, MD, USA and anti-rabbit IgG
from Vector, Burlingame, CA, USA). Proteins of interest were
revealed using West Pico chemiluminescence (Pierce) and viewed
in the luminescent image analyser Las-400 Mini (Fujifilm, Tokyo,
Japan).
Flow Cytometry for Cell Cycle Analysis
Cells were treated with 50 mM of resveratrol for 12 h. Cells
were then fixed with 70% cold ethanol and analysed after
propidium iodide staining. DNA content was determined by
FACSCalibur (Becton Dickinson, Franklin Lakes NJ, USA). Data
analysis was performed using FlowJo software, version 7.6.3
(Ashland, OR, USA).
Data Analysis
All data are reported as the mean 6 SD of triplicate
experiments. Results were analysed using the Student’s t-test. All
analyses were performed with GraphPad Prism software, version
5.02 (San Diego, CA, USA). A P-value ,0.05 was considered
significant.
Results
Effect of Resveratrol on NK Cell Line Proliferation,
Viability and Apoptosis
To investigate its potential anti-tumour activities, malignant
KHYG-1, NKL, NK-92 and NK-YS cells were cultured in the
presence of resveratrol. In a dose-dependent (Fig. 1A) and time-
dependent manner (Fig. 1B), resveratrol significantly inhibited
proliferation of all four cell lines. Resveratrol also induced dose-
dependent (Fig. 1C) and time-dependent (Fig. 1D) apoptosis in all
four lines. KHYG-1 cells were notably the most sensitive to
resveratrol (Figs. 1A, 1B, and 1C). To investigate morphological
changes induced by resveratrol, cells were stained with Giemsa. As
displayed in Figure 1E, cells undergoing resveratrol treatment
showed morphological signs of apoptosis such as nuclear
condensation [30] but were also preceded by cytoplasmic
vacuolisation at 12 hours of treatment.
Figure 1. NK cell line growth inhibition and apoptosis induced by resveratrol. Cells were plated in triplicate and treated with increasing
concentrations of resveratrol (3.125, 6.25, 12.5, 25 and 50 mM) for 48 h (A) or 50 mM for 24, 48 and 72 h (B). Cell proliferation was then evaluated using
the MTT assay. For the apoptosis study, cells (16106/ml) at 37uC were treated with resveratrol at the indicated concentrations for 24 h (C) or with
50 mM of resveratrol for the indicated times (D). The cells were then incubated with anti-annexin V antibody conjugated to FITC and analysed by flow
cytometry. Data represent the drug-induced increase in the percentage of apoptotic cells compared to the respective values observed in parallel
control cultures. Results are the mean of data, with error bars representing the SD of triplicate values. (E) Cells were treated with 50 mM of resveratrol
for 12 and 24 h and stained with Giemsa to observe morphological changes. The images shown are representative results of three independent
experiments.
doi:10.1371/journal.pone.0055183.g001
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Effect of Resveratrol on NK Cell Cycle Phase Distribution
Because previous reports found that resveratrol modulates the
expression of regulatory proteins involved in cell cycle progression
[12,31,32], its effect on NK cell cycle status was examined.
Treatment with 50 mM of resveratrol for 12 hours resulted in
a significant accumulation of cells in the G0/G1 phase for all four
cell lines (Figs. 2A and 2B) (P,0.05). This effect was associated
with a resveratrol-induced downregulation of cell-cycle regulator
proteins, such as cdc2, cdk2, and cdk3, for all four cell lines
(Fig. 2C), a finding consistent with a previous report in Burkkit’s
lymphoma cells [33]. This finding suggests that resveratrol anti-
tumour activity in malignant NK cells involves G0/G1 cell cycle
arrest.
Effect of Resveratrol on STAT3 and Apoptotic Protein
Activity
Since STAT3 signaling is required for NK cell survival and
proliferation [23] and previous studies showed that resveratrol is
a strong STAT3 inhibitor, the effect of resveratrol on STAT3
activation was investigated in malignant NK cells. As displayed in
Figure 3A, Western blot studies showed that all NK cell lines
constitutively expressed phosphorylated STAT3 at Tyr705.
Resveratrol notably had time- and dose-dependent kinetic effects
on inhibiting STAT3 phosphorylation in NK cell lines (Figs. 3A
and 3B). Acetylated STAT3, which recently attracted attention as
a tumour-promoting factor [34], was also constitutively expressed
by the four cell lines and had its expression markedly reduced by
resveratrol.
The effect of resveratrol on MCL1 and survivin was examined
because they mediate anti-apoptotic signals downstream of
STAT3 activation, and previous studies showed that malignant
NK cells constitutively express these proteins [20,35,36]. The
effect of resveratrol against other anti-apoptotic proteins including
Bcl-2 and Bcl-10 was also investigated. As shown in Figure 3C,
resveratrol strongly inhibited MCL1, Bcl-10 and survivin protein
expression in all four cell lines. Induction of apoptosis by
resveratrol was accompanied by cleavage of caspase 3 in all four
cell lines (Fig. 3D). The relations between STAT3 inhibition and
cell cycle distribution, apoptosis, MCL1 and survivin were also
confirmed in Figure S4 with STAT3 knock down by transient
transfection of STAT3 siRNA. These results suggest that STAT3
inhibition plays a role in resveratrol anti-tumour activities against
malignant NK cells.
Downregulation of JAK2 by Resveratrol
To elucidate potential mechanisms of resveratrol in STAT3
signaling inhibition, its effect on upstream regulators of STAT3
activation (the JAK family, PTEN and Akt) was examined.
Western blot studies showed that while constitutively active JAK1,
JAK2, PTEN and Akt were expressed in the four NK cell lines,
phosphorylated TYK2 was not detected in any of the cells studied.
Resveratrol treatment resulted in consistent inhibition of JAK2
phosphorylation but had no effect on the activation state of JAK1,
PTEN, Akt and TYK2 (Fig. 4). Interestingly, chemical inhibition
of JAK2 phosphorylation with AG490 vigorously induced
apoptosis in all four cell lines (Fig. S1A), and inhibited the
expression of STAT3 and its downstream proteins such as MCL1
and survivin (Fig. S1B), thus indicating that inhibition of the
JAK2/STAT3 pathway plays a crucial role in the anti-tumour
activities of resveratrol against malignant NK cells.
NK Cell Apoptosis Induced by Resveratrol via a p53-
independent Pathway
The role of p53 in resveratrol-induced apoptosis was in-
vestigated because previous studies showed that its anti-tumour
effects may be mediated in a p53-dependent or p53-independent
manner [37–39]. Total protein extracts from NK cells treated with
resveratrol were prepared, and their expression of total p53,
phosphorylated p53, p53 downstream protein p21 and p53
repressor Mdm2 were analysed by Western blot. Resveratrol did
not affect protein expression levels in the four cell lines studied
(Fig. 5A). In addition, NK cells pre-cultured with or without
pifithrin a, a p53 inhibitor which is by itself non-toxic to the NK
cell lines (Fig. S2), were equally susceptible to resveratrol-induced
apoptosis (Fig. 5B), indicating that functional p53 is not required
for resveratrol anti-tumour activity against malignant NK cells.
Synergistic Effect of Resveratrol Combined with L-
asparaginase
In vitro and clinical studies found that L-asparaginase is
a promising anticancer agent against NK malignancies [39,40].
To examine potential synergistic activity between resveratrol and
L-asparaginase against NK cell neoplasms, the four lines were
treated with L-asparaginase alone or with resveratrol and assessed
by flow cytometry to measure cell apoptosis. Consistent with
previous reports [2,40], L-asparaginase sensitivity varied among
the cell lines studied; NK-YS was highly sensitive, NK-92 and
NKL were moderately sensitive and KHYG-1 cells were resistant
to L-asparaginase (Fig. 6A). In contrast to resveratrol, apoptosis
induced by L-asparaginase was not preceded by autophagy-like
changes (Fig. S3), indicating that the anti-tumour activities of those
compounds are mediated by different mechanisms. Remarkably,
L-asparaginase with resveratrol resulted in a synergistic cytotoxic
effect against KHYG-1, NKL and NK-92 cells (Figs. 6B and 6C).
The synergistic effect was not observed in NK-YS cells (data not
shown) presumably because of the extremely high sensitivity of this
cell line to L-asparaginase (Fig. 6A).
Discussion
This study demonstrated that resveratrol, a naturally occurring
polyphenol, strongly inhibited the growth and survival of
malignant NK cells. Mechanism studies revealed that resveratrol
inhibits constitutively active STAT3 signaling, leading to down-
regulation of the anti-apoptotic proteins MCL1, Bcl-10, and
survivin. These events contributed to cell cycle arrest at G0/G1
and eventual loss of viability due to apoptosis.
STAT proteins function as downstream effectors of growth
factor receptors and cytokine signals that participate in vital
processes such as cell proliferation and apoptosis [41]. STAT3 is
constitutively activated in human solid tumour cancers such as
breast cancer and prostate cancer, as well as myelomas and NK
Figure 2. Effect of resveratrol on NK cell cycle distribution. (A) Cells were treated with 50 mM of resveratrol for 12 h and stained with
propidium iodide. DNA content was analysed by flow cytometry. The representative results of three independent experiments are shown. (B) Results
are the mean of data, with error bars representing the SD of triplicate values. (C) Cells were treated with 50 mM of resveratrol for 24, 36 and 48 h.
50 mg of whole cell extract was prepared for each cell line, separated with SDS-PAGE and subjected to Western blotting with antibodies specific to
cdc2, cdk2 and cdk3. The blots were stripped and reprobed with a-tubulin antibody to show equal protein loading. The figures shown are
representative results of three independent experiments.*P,0.05.
doi:10.1371/journal.pone.0055183.g002
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Figure 3. Effect of resveratrol on STAT3 activity and anti-apoptotic proteins in NK cell lines. Cells were treated with 50 mM of resveratrol
for 24, 36 and 48 h. 50 mg of whole cell extract was prepared for each cell line, separated with SDS-PAGE and subjected to Western blotting with
antibodies specific to acetylated STAT3 (Ac-STAT3), phosphorylated STAT3 (p-STAT3) and STAT3 (A) or MCL1, Bcl-2, Bcl-10 and survivin (C) or cleaved
caspase 3 (D). KHYG-1 cells were treated with the indicated concentrations of resveratrol for 24 h (B). The blots were stripped and reprobed with a-
tubulin antibody to show equal protein loading. The figures shown are representative results of three independent experiments.
doi:10.1371/journal.pone.0055183.g003
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cell lymphomas [21,23,42–46]. Aberrant STAT3 signaling in
malignant cells thus represents a promising therapeutic target. Our
findings show that resveratrol effectively inhibits STAT3 in
malignant NK cells, which agrees with other studies that found
the polyphenol was an efficacious inhibitor of constitutively active
STAT3 in malignant cells [47,48]. Our findings that resveratrol
inhibited STAT-3 as well as its downstream anti-apoptotic
proteins MCL-1 and survivin are also consistent with its effect
on EBV-infected B cells in our previous study [49]. The expression
of the anti-apoptotic protein Bcl-2 was not affected by the
resveratrol-induced JAK2 inhibition which is consistent with the
report by Tsutsui et al [20], showing that JAK2 inhibition with
AG490 does not down-regulate Bcl-2 protein in malignant NK
cells.
A previous study showed that leukaemic cells lacking functional
p53 are L-asparaginase resistant [50]. This is consistent with our
finding that KHYG-1 cells with a P53 mutation [25] were resistant
to L-asparaginase. Remarkably, the other three cell lines NKL,
NK-92 and NK-YS, all of which express wild type P53 protein as
reported in previous studies [51,52], were more sensitive to L-
asparaginase treatment. Interestingly, KHYG-1 cells were the
most sensitive to resveratrol treatment of the four NK cell lines.
Efficient induction of apoptosis by resveratrol in NK cells lacking
functional p53 is consistent with a report that resveratrol induced
both p53-dependent and p53-independent apoptosis [53].
In contrast to previous studies where resveratrol enhanced the
function of tumour suppressor PTEN and inhibited activated Akt
in tumour cells [47,54], resveratrol treatment in this study did not
affect expression of JAK1, PTEN, TYK2 and Akt. The inhibitory
effect of resveratrol on STAT3 activation was mediated by
inhibition of phosphorylated JAK2 in all four NK cell lines. This is
consistent with our findings that the cell lines underwent apoptosis
and STAT3 signaling was strongly inhibited when exposed to the
JAK2 inhibitor AG490 (Fig. S1), as well as a previous report on
NK-YS cells treated with AG490 [20]. Resveratrol-induced JAK2
inhibition is further supported by our findings showing reduction
of phosphorylated JAK2 and resveratrol induced apoptosis in
HEL cells (data not shown), a myeloid cell line with a JAK2
activation mutation [55]. These findings collectively suggest that
resveratrol is a JAK2 inhibitor with considerable clinical relevance,
given that dysregulated JAK2 activity is involved in the
pathogenesis of hematological diseases such as myeloproliferative
neoplasms [56].
One intriguing finding of this study was that resveratrol-induced
apoptosis was preceded by cellular morphological changes
characterized by accumulation of autophagic vacuoles in the
cytoplasm. The absence of these changes in NK cells treated with
L-asparaginase (Fig. S3) supports the notion that these compounds
exert their anti-tumour effects through different mechanisms.
Apoptotic cell death and autophagic cell death have been broadly
accepted as two separate mechanisms of programmed cell death,
although recent reports suggest that autophagic vacuole accumu-
lation could precede apoptotic cell death [30]. Interestingly,
similar morphological changes have been reported in human
colorectal DLD1 cancer cells treated with resveratrol [57].
Previous studies revealed that resveratrol is a potent activator of
sirtuin 1 (SIRT1) [58–62] and that SIRT1 mediates down-
regulation of acetylated STAT3 in various cellular systems [63,64].
This is consistent with our finding that acetylated STAT3
decreased in NK cell lines treated with resveratrol and supports
Figure 4. Effect of resveratrol on STAT3 upstream proteins in NK cell lines. Cells were treated with 50 mM of resveratrol for 24, 36 and 48 h.
50 mg of whole cell extract was prepared for each cell line, separated on SDS-PAGE and subjected to Western blotting with antibodies specific to
phosphorylated JAK1 (p-JAK1), JAK1, phosphorylated TYK2 (p-TYK2), phosphorylated Akt (p-Akt), phosphorylated PTEN (p-PTEN), phosphorylated
JAK2 (p-JAK2) and JAK2. The blots were stripped and reprobed with anti-a-tubulin antibody to show equal protein loading. The figures shown are
representative results of three independent experiments.
doi:10.1371/journal.pone.0055183.g004
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Figure 5. Effect of resveratrol on the p21/p53 axis and Mdm2/p53 axis in NK cell lines. (A) Cells were treated with 50 mM of resveratrol for
24, 36 and 48 h. 50 mg of whole cell extract was prepared for each cell line, separated by SDS-PAGE and subjected to Western blotting with
antibodies specific to Mdm2, p53 and p21 antibodies. The blots were stripped and reprobed with anti- a-tubulin antibody to show equal protein
loading. (B) Cells (16106/ml) were incubated with pifithrin a for 2 h in one group before treatment of 50 mM of resveratrol for 24 h. The cells were
then incubated with anti-annexin V antibody conjugated to FITC and analysed by flow cytometry to evaluate apoptosis. The figures shown are
representative results of three independent experiments.
doi:10.1371/journal.pone.0055183.g005
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the concept that STAT3 deacetylation is a contributing anti-
tumour property. Although this study did not investigate
downstream effects of resveratrol-induced STAT3 deacetylation,
a recent report demonstrated that acetylated STAT3 methylates
the promoter region of tumor suppressor genes and results in gene
silencing that promotes tumour cell proliferation. The same study
also showed that inhibition of STAT3 acetylation by resveratrol
results in promoter demethylation, restoring the expression of
tumour suppressor genes [34].
In conclusion, our data indicate that resveratrol has potent anti-
tumour effects against malignant NK cells that are mediated
through inhibition of constitutively active STAT3 signals due to
blocking JAK2 kinase. This study is the first to demonstrate that
resveratrol is a potent JAK2 inhibitor. As a result, resveratrol may
have therapeutic potential against not only NK neoplasms but also
haematological disorders where dysregulated JAK2 signaling plays
a critical role in pathogenesis.
Supporting Information
Figure S1 Effect of JAK2 inhibitor AG490 in NK cell
lines. Cells (16106/ml) were treated with 100 mM of AG490 for
24 and 48 h. The cells were then incubated with anti-annexin V
antibody conjugated to FITC and analysed by flow cytometry to
evaluate apoptosis. (B) Cells were treated with 100 mM of AG490
for 24, 36 and 48 h. 50 mg of whole cell extract was prepared for
each cell line, separated by SDS-PAGE, and subjected to Western
blotting with antibodies specific to phosphorylted STAT3 (p-
STAT3), STAT3, MCL1, and survivin. The blots were stripped
and reprobed with anti-a-tubulin antibody to show equal protein
loading. Figures shown are representative results of three
independent experiments.
(TIF)
Figure S2 Apoptotic effect of a p53 inhibitor pifithrin
a in NK cell lines. Cells (16106/ml) were treated with 30 mM of
pifithrin a for 24 h. The cells were then incubated with anti-
annexin V antibody conjugated to FITC and analyzed by flow
cytometry to evaluate apoptosis. Figures shown are representative
results of three independent experiments.
(TIF)
Figure S3 Effect of L-aparaginase on NK cell morphol-
ogy. Cells were treated with 10 IU/ml of L-asparaginase for 12
and 24 h and stained with Giemsa to observe morphological
changes. The images shown are representative results of three
independent experiments.
(TIF)
Figure S4 Effect of STAT3 siRNA on cell cycle pro-
gression, apoptosis and STAT3 signaling in NK cell
lines. Cell cycle analysis (A), Annexin V staining (B) and Western
blotting with antibodies specific to phosphorylated STAT3,
STAT3, MCL1, and survivin (C) were performed at 48 h after
transfection with STAT3 siRNA. The representative results of two
or more independent experiments are shown.
(TIF)
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